The antiatherogenic dose response effect of verapamil in an experimental atherosclerosis model in the rabbit
Language English Country Czech Republic Media print
Document type Journal Article
PubMed
1842941
Knihovny.cz E-resources
- MeSH
- Aorta, Thoracic pathology MeSH
- Arteriosclerosis pathology MeSH
- beta-Galactosidase blood MeSH
- Cholesterol, Dietary administration & dosage MeSH
- Cholesterol blood MeSH
- Dipeptidyl-Peptidases and Tripeptidyl-Peptidases blood MeSH
- Esterases blood MeSH
- Glucosephosphate Dehydrogenase blood MeSH
- Rabbits MeSH
- Blood Pressure physiology MeSH
- Acid Phosphatase blood MeSH
- Muscle, Smooth, Vascular pathology MeSH
- Triglycerides blood MeSH
- Verapamil pharmacology MeSH
- Animals MeSH
- Check Tag
- Rabbits MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- beta-Galactosidase MeSH
- Cholesterol, Dietary MeSH
- Cholesterol MeSH
- Dipeptidyl-Peptidases and Tripeptidyl-Peptidases MeSH
- Esterases MeSH
- Glucosephosphate Dehydrogenase MeSH
- Acid Phosphatase MeSH
- Triglycerides MeSH
- Verapamil MeSH
The aim of the study was to assess the dose dependence of the antiatherogenic effect of verapamil (Isoptin, Lek Ljubljana, Yugoslavia) in rabbits fed 1% cholesterol diet. Verapamil was administered subcutaneously at doses of 0.25, 1 and 2 mg.kg-1/day at 12-hour intervals for 8 weeks. The results indicate verapamil administered s.c. exerts a preventive anti-atherosclerotic effect only in therapeutic doses (0.25 mg.kg-1). The beneficial effect of low-dose verapamil can also be seen in the spectrum of serum lipids as the drug lowers the levels of total cholesterol and triacylglycerols. Compared with the results obtained from a group receiving diet without Ca-antagonist premedication, high doses do not reduce the extent of atheromatous plaques.
